U.S. Paper and Forestry Products Stock News

Why N-able (NABL) is on investors’ radar N-able (NABL) has drawn investor attention after recent trading left the stock at US$5.35, with returns over the past month and past 3 months under pressure and the 1 year total return also negative. With annual revenue of US$497.665 million and net income reported as a US$6.511 million loss, the company’s value score of 6 and an indicated intrinsic discount provide a starting point for investors assessing risk and potential reward. See our latest...

If you are trying to figure out whether Madrigal Pharmaceuticals is priced attractively today, you will want to look beyond the share price and consider what different valuation methods are signaling. The stock closed at US$464.71, with a 2.7% decline over 7 days, a 7.4% decline over 30 days, a 21.7% decline year to date, a 37.8% gain over 1 year, a 53.2% gain over 3 years, and a 281.3% gain over 5 years. These figures can influence how investors think about both upside potential and...

Wondering if Klarna Group at US$18.11 is a bargain or a value trap? This article walks you through what the current price might really be telling you. The stock has recently seen sharp moves, with a 7 day return of an 11.7% decline and a 30 day return of a 37.6% decline, and it sits 36.6% below its year to date level. Recent headlines around Klarna Group have kept investor attention on the business model and competitive position, which helps frame these price swings. This article uses that...

Ford Motor (NYSE:F) is in talks with US and European authorities and Chinese automakers, including Geely, about potential joint ventures and technology partnerships. Discussions with Trump administration officials focus on frameworks that could allow Chinese EV makers to operate in the US through joint ventures with American majority control. Parallel talks in Europe involve using Ford’s excess production capacity to build vehicles for Geely and share advanced vehicle technology, including...

Why Tempus AI’s new lung cancer screening partnership matters Tempus AI (TEM) just announced a collaboration with Median Technologies to bring FDA cleared eyonis LCS lung cancer screening software into the Tempus Pixel platform, putting more focus on early detection and clinical workflows. See our latest analysis for Tempus AI. The Median partnership arrives after a choppy stretch for Tempus AI, with a 1 day share price return of 2.30% to US$51.95, following a 30 day share price return...

Crane NXT recently reported past quarterly results showing around 20% year-on-year sales growth in Q4 2025 and 11% for 2025 overall, driven by strong demand in its currency and authentication technology businesses, new wins across 20 currency denominations, and renewed multiyear contracts with major sports leagues. The company is also expanding capacity in its international currency operations and moving to acquire Antares Vision by mid-2026, highlighting how its micro-optics and...

Recent performance snapshot for ServisFirst Bancshares ServisFirst Bancshares (SFBS) has drawn investor attention after a recent share price move, with the stock around $86.14 and showing mixed return patterns across the past year and multi year periods. See our latest analysis for ServisFirst Bancshares. Recent trading has been relatively steady, with a 30 day share price return of 10.07% and a 90 day share price return of 26.27%, while the 1 year total shareholder return of 0.93% decline...

On 12 February 2026, BioLife Solutions, Inc. announced a multi-year agreement to distribute Qkine Limited’s cytokine and growth factor products globally for cell and gene therapy manufacturing, with plans to integrate select products into BioLife’s CellSeal® Connect vial system. This deal broadens BioLife’s reach into the US$500 million cytokines market, which third-party research suggests could reach about US$1.00 billion by 2030, directly linking its biopreservation tools with critical CGT...

If you are wondering whether Flex stock still offers value after a strong run, this article will help you unpack what the current price might be implying about the business. The shares recently closed at US$64.24, with returns of 0.4% over 7 days, a 0.9% decline over 30 days, 0.9% year to date and 51.1% over 1 year. This naturally raises questions about how much of the story is already in the price. Recent news coverage around Flex has focused on its role as a large electronics manufacturing...

Upstart Holdings, Inc. reported fourth‑quarter 2025 revenue of US$296.09 million and net income of US$18.64 million, marking a return to profitability for both the quarter and full year compared with losses in 2024. Alongside these results, Upstart unveiled an extensive leadership reshuffle and issued multi‑year revenue guidance through 2028, signaling a shift in how it balances growth ambitions with execution and governance. We’ll now examine how Upstart’s return to profitability and...

Conference spotlight and access program put Syndax Pharmaceuticals (SNDX) in focus Syndax Pharmaceuticals (SNDX) is back on investors radar after positive Revuforj trial data, a new Managed Access Program with the World Orphan Drug Alliance, and a high profile slot at Guggenheim Securities Emerging Outlook Biotech Summit 2026. See our latest analysis for Syndax Pharmaceuticals. Despite a softer patch recently, with a 1 day share price return of a 3.12% decline and a 7 day share price return...

NeoVolta (NEOV) has just posted its Q2 2026 numbers, with Q1 2026 revenue at US$6.7 million and a net loss of US$1.2 million, translating into basic EPS of a US$0.04 loss. The company has seen quarterly revenue move from US$0.6 million in Q1 2025 through US$1.1 million in Q2 2025, US$2.0 million in Q3 2025 and US$4.8 million in Q4 2025 to US$6.7 million in Q1 2026, while EPS over the same stretch ranged from a loss of US$0.03 to a loss of US$0.05 per share. For investors, the latest set of...

Why EPAM Systems (EPAM) Is Back on Investors’ Radar Fresh attention on EPAM Systems (EPAM) follows research highlighting its stronger earnings outlook and value metrics versus Infosys, positioning the US software services group as a comparatively attractive IT services option. See our latest analysis for EPAM Systems. At a share price of US$166.37, EPAM has seen a sharp 21.75% 1 month share price decline and a 37.48% 1 year total shareholder return decline. This suggests recent earnings and...

If you are wondering whether Oracle's share price still reflects good value or is already pricing in a lot of optimism, this article will walk through what the current market price might be implying. Oracle recently closed at US$160.14, with returns of 12.1% over the past week, a 16.2% decline over the past month, an 18.2% decline year to date, a 7.1% decline over the past year, 90.2% over three years and 180.5% over five years. Together, these figures give a mixed picture for anyone trying...

Why ZTO Express (Cayman) (ZTO) is in focus now ZTO Express (Cayman) (ZTO) recently issued 2025 earnings guidance that combines projected revenue growth with a lower gross profit range, while also completing a US$1.5b convertible bond offering maturing in 2031. See our latest analysis for ZTO Express (Cayman). The earnings guidance and US$1.5b convertible bond come after a strong run in the share price, with a 30-day share price return of 10.48% and a 90-day share price return of 30.75%. The...

nLIGHT (LASR) is back in focus after completing a US$175 million follow on equity offering and spotlighting its defense focused laser portfolio, with investors weighing what this fresh capital and product emphasis could mean. See our latest analysis for nLIGHT. The recent capital raise and defense product push come after a powerful run, with an approximately 77% 3 month share price return and a very large 1 year total shareholder return of around 423%. This suggests strong momentum rather...

Tapestry (NYSE:TPR) reported strong quarterly results, highlighting global customer acquisition and growing Gen Z engagement. Management pointed to increased effectiveness of its direct to consumer approach, marketing efforts, and product development. The company raised its full year revenue outlook, citing higher operating margins and improved profitability. Tapestry, the owner of several luxury and premium brands, is drawing attention after this update, especially given its recent share...

If you are wondering whether TPG’s share price reflects its underlying worth right now, you are not alone. This article is here to frame the key valuation questions you might be asking. After reaching a recent close of US$49.53, the stock has seen a 10% decline over the last 7 days and a 26.2% decline over the last 30 days, while still showing a 64.5% return over 3 years and mixed results over shorter periods including year to date and the last 12 months. Recent news coverage around TPG has...

Why EPR Properties Is On Investors’ Radar EPR Properties (EPR) has attracted attention after recent share price moves, with the stock last closing at $58.49. Investors are weighing this against its reported $707.15 million in revenue and $175.493 million in net income. See our latest analysis for EPR Properties. Recent share price momentum has been firm, with a 16.1% 90 day share price return and 15.2% year to date share price return. The 5 year total shareholder return of 88.1% points to a...

Why CSW Industrials Is Back On Investors’ Radar Investor sentiment toward CSW Industrials (CSW) has shifted, with buyers returning after a stretch of earnings misses, as attention turns to the company’s multi-year revenue and net income growth and longer term outlook. See our latest analysis for CSW Industrials. At a share price of US$309.48, CSW Industrials has recently seen a 6.63% 7 day share price return but a 6.53% 30 day share price decline, while its 90 day share price return of 28.25%...

QuantumScape (QS) is back in focus after reporting fourth quarter and full year 2025 results. The company narrowed its annual net loss to US$435.05 million while pushing ahead with its Eagle Line solid state battery pilot production. See our latest analysis for QuantumScape. The recent Q4 report, Eagle Line inauguration and board changes have come against a weak stretch of momentum, with a 30 day share price return of 26.73% decline and a five year total shareholder return of 87.58% loss,...

Why Kingsoft Cloud Holdings (KC) Is Back on Investor Radars Kingsoft Cloud Holdings (NasdaqGS:KC) is drawing fresh interest after reporting revenue growth of 31.40% and attracting consistent buy ratings from analysts, even as profitability and cash flow remain key watchpoints for investors. See our latest analysis for Kingsoft Cloud Holdings. Recent trading has been volatile, with a 7 day share price return of 11.99% and a 30 day gain of 21.68%. However, the 1 year total shareholder return...

Curtiss-Wright (NYSE:CW) has been selected by Boeing to supply mission computer technology for the U.S. Air Force C-17 Globemaster III upgrade program. The contract, valued at over $400 million, supports modernization of a key airlift platform used by the U.S. and allied forces. This award expands Curtiss-Wright's role in military aerospace technology and deepens its relationship with Boeing. Curtiss-Wright comes into this contract win with shares at $684.22, after a 1-year return of 112.1%...

On February 4, 2026, Oncolytics Biotech announced that the FDA granted Fast Track Designation to pelareorep combined with bevacizumab and FOLFIRI for second-line treatment of KRAS-mutant, microsatellite-stable metastatic colorectal cancer. The designation is backed by clinical data showing pelareorep-based therapy delivered higher response rates and longer survival measures than existing standard-of-care options in this hard-to-treat subgroup. With the FDA’s Fast Track Designation in place,...